Boston Scientific Corp. Files Definitive Proxy Statement

Ticker: BSX · Form: DEF 14A · Filed: Mar 20, 2024 · CIK: 885725

Boston Scientific CORP DEF 14A Filing Summary
FieldDetail
CompanyBoston Scientific CORP (BSX)
Form TypeDEF 14A
Filed DateMar 20, 2024
Risk Levellow
Pages15
Reading Time19 min
Key Dollar Amounts$76 million
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, Boston Scientific, Executive Compensation, Corporate Governance

TL;DR

<b>Boston Scientific Corp. has filed its Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023.</b>

AI Summary

BOSTON SCIENTIFIC CORP (BSX) filed a Proxy Statement (DEF 14A) with the SEC on March 20, 2024. Filing type is DEF 14A, indicating a definitive proxy statement. Company name is Boston Scientific Corp. (BSX). Reporting period covers fiscal year ending December 31, 2023. Includes data for fiscal years 2020, 2021, 2022, and 2023. Address: 300 Boston Scientific Way, Marlborough, MA 01752-1234.

Why It Matters

For investors and stakeholders tracking BOSTON SCIENTIFIC CORP, this filing contains several important signals. This filing is a standard regulatory requirement for public companies to disclose information related to shareholder meetings and executive compensation. The DEF 14A provides detailed information on executive compensation, director elections, and other corporate governance matters, which are crucial for investors to make informed decisions.

Risk Assessment

Risk Level: low — BOSTON SCIENTIFIC CORP shows low risk based on this filing. The filing is a routine DEF 14A, containing standard disclosures without immediate financial or operational red flags.

Analyst Insight

Review the executive compensation details and any proposals to be voted on at the upcoming shareholder meeting to understand management's incentives and strategic direction.

Key Numbers

Key Players & Entities

FAQ

When did BOSTON SCIENTIFIC CORP file this DEF 14A?

BOSTON SCIENTIFIC CORP filed this Proxy Statement (DEF 14A) with the SEC on March 20, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BOSTON SCIENTIFIC CORP (BSX).

Where can I read the original DEF 14A filing from BOSTON SCIENTIFIC CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BOSTON SCIENTIFIC CORP.

What are the key takeaways from BOSTON SCIENTIFIC CORP's DEF 14A?

BOSTON SCIENTIFIC CORP filed this DEF 14A on March 20, 2024. Key takeaways: Filing type is DEF 14A, indicating a definitive proxy statement.. Company name is Boston Scientific Corp. (BSX).. Reporting period covers fiscal year ending December 31, 2023..

Is BOSTON SCIENTIFIC CORP a risky investment based on this filing?

Based on this DEF 14A, BOSTON SCIENTIFIC CORP presents a relatively low-risk profile. The filing is a routine DEF 14A, containing standard disclosures without immediate financial or operational red flags.

What should investors do after reading BOSTON SCIENTIFIC CORP's DEF 14A?

Review the executive compensation details and any proposals to be voted on at the upcoming shareholder meeting to understand management's incentives and strategic direction. The overall sentiment from this filing is neutral.

How does BOSTON SCIENTIFIC CORP compare to its industry peers?

Boston Scientific Corp. operates in the surgical and medical instruments & apparatus industry.

Are there regulatory concerns for BOSTON SCIENTIFIC CORP?

This filing is made under the Securities Exchange Act of 1934, requiring public companies to provide detailed information to shareholders.

Industry Context

Boston Scientific Corp. operates in the surgical and medical instruments & apparatus industry.

Regulatory Implications

This filing is made under the Securities Exchange Act of 1934, requiring public companies to provide detailed information to shareholders.

What Investors Should Do

  1. Analyze executive compensation packages and equity awards for key executives.
  2. Review proposals to be presented at the shareholder meeting, such as director elections and advisory votes on executive compensation.
  3. Compare executive compensation trends with industry peers if comparative data is available in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure. Specific year-over-year comparisons of financial metrics are not directly available in this document type, but it provides context for executive compensation and governance over multiple years.

Filing Stats: 4,647 words · 19 min read · ~15 pages · Grade level 13 · Accepted 2024-03-20 17:06:32

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 79 Pay Versus Performance 105 Equity Compensation Plans 110 Proposal 2 Advisory Vote to Approve the Compensation of our Named Executive Officer s 111 Proposal 3 Amend and Restate o ur By-Laws to Provide for A dvance Notice and Universal Proxy Rule Updates 113 Audit Committee Report 116 Proposal 4 Ratification of Appointment of our Independent Registered Public Accounting Firm 117 Stockholder Proposals and Company Information 119 Other Information 120 Annex A - Reconciliations of Non-GAAP Financial Measures Used in Incentive Compensation Plans and Programs A - 1 Annex B - Amended and Restated By-Laws of Boston Scientific Corporation B - 1 2024 Proxy Statement 7 Information About the Annual Meeting and Voting The Annual Meeting The 2024 Annual Meeting of Stockholders (Annual Meeting) of Boston Scientific Corporation (the Company) will be held on Thursday, May 2, 2024, at 8:00 a.m. Eastern Time. To maximize stockholder participation and provide a consistent experience regardless of location, our Annual Meeting will be held in a virtual format only, via live webcast over the internet. You will be able to join the Annual Meeting and vote and submit your questions online during the Annual Meeting by visiting www.virtualshareholdermeeting.com/BSX2024 . We have designed the virtual Annual Meeting to ensure stockholders are afforded the same opportunity to participate as they would have at an in-person meeting, including the right to vote and ask questions through the virtual meeting platform. At this meeting, stockholders will be asked to elect nine nominees for director; approve, on a non-binding, advisory basis, the compensation of our named executive officers; approve an amendment and restatement of our By-Laws to provide for advance notice and universal proxy rule updates; and ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2024 fiscal year. Managemen

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing